Revolutionizing Crohn’s and Colitis Treatment: Altrubio Unveils Groundbreaking Immune Booster at 2023 Congress!
Welcome to AltruBio’s Exciting Announcement! San Francisco, Jan. 19, 2023 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that David T. Rubin, M.D., Professor of Medicine at the University…